Search Results

You are looking at 81 - 90 of 112 items for :

  • "aromatase inhibitor" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Jennifer Barsky Reese, Lauren A. Zimmaro, Sharon L. Bober, Kristen Sorice, Elizabeth Handorf, Elaine Wittenberg, Areej El-Jawahri, Mary Catherine Beach, Antonio C. Wolff, Mary B. Daly, Brynna Izquierdo, and Stephen J. Lepore

main ideas that all patients should receive a discussion of sexual issues, but then certain groups of patients, including those on aromatase inhibitors and ovarian suppression, require special care due to the severity and abruptness of sexual problems

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

effects of aromatase inhibitors versus tamoxifen: the patients’ perspective . Am J Surg 2006 ; 192 : 496 – 498 . 16978958 10.1016/j.amjsurg.2006.06.018 25. Vogel CL , Cobleigh MA , Tripathy D , . First-line Herceptin monotherapy in metastatic

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. the panel, the endocrine therapy options include an aromatase inhibitor

Full access

Kathleen Harnden and Kimberly Blackwell

/ABCSG XX) . Presented at the 2013 San Antonio Breast Cancer Symposium ; December 13, 2013 ; San Antonio, Texas . 25. Llombart A Frassoldati A Paija O . Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

treatment consisted of tamoxifen or aromatase inhibitor according to hormonal receptor status and menopausal status. Statistical Analyses Statistical analyses were performed with SPSS Statistics for Windows, Version 19.0 (IBM Corp, Armonk, NY

Full access

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

“consider checking 25-hydroxy vitamin D levels.” Justification: Insufficient and deficient vitamin D levels have been associated with poorer outcome among women with breast cancer in Canada. 32 Aromatase inhibitors can cause secondary osteopenia and

Full access

Parijatham S. Thomas

(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo

Full access

Leslie R. Schover, Ying Yuan, Bryan M. Fellman, Evan Odensky, Pamela E. Lewis, and Paul Martinetti

aromatase inhibitors, 7 direct genital damage from pelvic radiation therapy, 8 - 10 and genital graft-versus-host disease. 11 Urinary and fecal incontinence often lead to avoidance of sexual contact. 12 The recent NCCN Clinical Practice Guidelines in

Full access

chemotherapy. Methods: This study used the MarketScan and PharMetrics claims databases (January 1, 2002–June 30, 2014) to identify postmenopausal women with HR+/HER2− mBC who failed a nonsteroidal aromatase inhibitor and later initiated a new line of therapy

Full access

Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam F. Ponde, Andrea Gombos, Vicki Paterson, Florentine Hilbers, Larissa Korde, Anna Manukyants, Amylou Dueck, Christian Maurer, Martine Piccart, Alvaro Moreno-Aspitia, Christine Desmedt, Serena Di Cosimo, and Evandro de Azambuja

with obesity were more likely to have been treated with mastectomy ( P <.001), anthracycline-based chemotherapy ( P <.001), and aromatase inhibitors ( P <.001) ( Table 1 ). Table 1. Patient Demographics and Clinical Characteristics by BMI a Prognostic